Long-term outcome of surgical resection for residual or regrown advanced non-small cell lung carcinomas following EGFR-TKI treatment

report of four cases

Tomoyuki Hishida, Junji Yoshida, Keiju Aokage, Kanji Nagai, Masahiro Tsuboi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We report the long-term outcome of 4 patients who underwent pulmonary resection for residual or regrown primary lesion of non-small cell lung cancer (NSCLC) treated with a epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) gefitinib. Two patients underwent surgical resection for localized regrown primary lesion after gefitinib for stage IV disease. The remaining two patients underwent surgery for localized residual primary lesion that was downstaged to N0 after gefitinib for initially inoperable cN2 (stage IIIA) disease. Three patients developed recurrence with a median progression-free period of 1.2 years (0.2–2.2), but they survived more than 5 years postoperatively with good local control. One patient who initially had cN2 disease is alive without recurrence after 4 years with continued postoperative gefitinib. Although our series is small, the relatively favorable long-term survival indicates the need for further investigation of the role of surgery during molecular-targeted therapy for advanced NSCLC.

Original languageEnglish
Pages (from-to)429-433
Number of pages5
JournalGeneral Thoracic and Cardiovascular Surgery
Volume64
Issue number7
DOIs
Publication statusPublished - 2016 Jul 1
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Molecular Targeted Therapy
Therapeutics
Recurrence
Lung
Survival
gefitinib

Keywords

  • EGFR-TKI
  • Local therapy
  • Non-small cell lung cancer
  • Surgery

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Pulmonary and Respiratory Medicine

Cite this

Long-term outcome of surgical resection for residual or regrown advanced non-small cell lung carcinomas following EGFR-TKI treatment : report of four cases. / Hishida, Tomoyuki; Yoshida, Junji; Aokage, Keiju; Nagai, Kanji; Tsuboi, Masahiro.

In: General Thoracic and Cardiovascular Surgery, Vol. 64, No. 7, 01.07.2016, p. 429-433.

Research output: Contribution to journalArticle

@article{fa3e277b350249ab8566b92e26d9ea25,
title = "Long-term outcome of surgical resection for residual or regrown advanced non-small cell lung carcinomas following EGFR-TKI treatment: report of four cases",
abstract = "We report the long-term outcome of 4 patients who underwent pulmonary resection for residual or regrown primary lesion of non-small cell lung cancer (NSCLC) treated with a epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) gefitinib. Two patients underwent surgical resection for localized regrown primary lesion after gefitinib for stage IV disease. The remaining two patients underwent surgery for localized residual primary lesion that was downstaged to N0 after gefitinib for initially inoperable cN2 (stage IIIA) disease. Three patients developed recurrence with a median progression-free period of 1.2 years (0.2–2.2), but they survived more than 5 years postoperatively with good local control. One patient who initially had cN2 disease is alive without recurrence after 4 years with continued postoperative gefitinib. Although our series is small, the relatively favorable long-term survival indicates the need for further investigation of the role of surgery during molecular-targeted therapy for advanced NSCLC.",
keywords = "EGFR-TKI, Local therapy, Non-small cell lung cancer, Surgery",
author = "Tomoyuki Hishida and Junji Yoshida and Keiju Aokage and Kanji Nagai and Masahiro Tsuboi",
year = "2016",
month = "7",
day = "1",
doi = "10.1007/s11748-014-0508-5",
language = "English",
volume = "64",
pages = "429--433",
journal = "General Thoracic and Cardiovascular Surgery",
issn = "1863-6705",
publisher = "Springer Japan",
number = "7",

}

TY - JOUR

T1 - Long-term outcome of surgical resection for residual or regrown advanced non-small cell lung carcinomas following EGFR-TKI treatment

T2 - report of four cases

AU - Hishida, Tomoyuki

AU - Yoshida, Junji

AU - Aokage, Keiju

AU - Nagai, Kanji

AU - Tsuboi, Masahiro

PY - 2016/7/1

Y1 - 2016/7/1

N2 - We report the long-term outcome of 4 patients who underwent pulmonary resection for residual or regrown primary lesion of non-small cell lung cancer (NSCLC) treated with a epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) gefitinib. Two patients underwent surgical resection for localized regrown primary lesion after gefitinib for stage IV disease. The remaining two patients underwent surgery for localized residual primary lesion that was downstaged to N0 after gefitinib for initially inoperable cN2 (stage IIIA) disease. Three patients developed recurrence with a median progression-free period of 1.2 years (0.2–2.2), but they survived more than 5 years postoperatively with good local control. One patient who initially had cN2 disease is alive without recurrence after 4 years with continued postoperative gefitinib. Although our series is small, the relatively favorable long-term survival indicates the need for further investigation of the role of surgery during molecular-targeted therapy for advanced NSCLC.

AB - We report the long-term outcome of 4 patients who underwent pulmonary resection for residual or regrown primary lesion of non-small cell lung cancer (NSCLC) treated with a epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) gefitinib. Two patients underwent surgical resection for localized regrown primary lesion after gefitinib for stage IV disease. The remaining two patients underwent surgery for localized residual primary lesion that was downstaged to N0 after gefitinib for initially inoperable cN2 (stage IIIA) disease. Three patients developed recurrence with a median progression-free period of 1.2 years (0.2–2.2), but they survived more than 5 years postoperatively with good local control. One patient who initially had cN2 disease is alive without recurrence after 4 years with continued postoperative gefitinib. Although our series is small, the relatively favorable long-term survival indicates the need for further investigation of the role of surgery during molecular-targeted therapy for advanced NSCLC.

KW - EGFR-TKI

KW - Local therapy

KW - Non-small cell lung cancer

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=84918534283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918534283&partnerID=8YFLogxK

U2 - 10.1007/s11748-014-0508-5

DO - 10.1007/s11748-014-0508-5

M3 - Article

VL - 64

SP - 429

EP - 433

JO - General Thoracic and Cardiovascular Surgery

JF - General Thoracic and Cardiovascular Surgery

SN - 1863-6705

IS - 7

ER -